167
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis

ORCID Icon, ORCID Icon, , , , , & show all
Pages 231-237 | Published online: 23 Jan 2020

References

  • Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM. Multimodal intrathecal analgesia in refractory cancer pain. Scand J Pain. 2017;14:39–43. doi:10.1016/j.sjpain.2016.10.002
  • van den Beuken-van EM, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449. doi:10.1093/annonc/mdm056
  • De Andres J, Rubio-Haro R, De Andres-serrano C, Asensio-Samper JM, Fabregat-Cid G. Intrathecal drug delivery. Methods Mol Biol. 2020;2059:75–108. doi: 10.1007/978-1-4939-9798-5_3
  • Bhatia G, Lau ME, Koury KM, Gulur P. Intrathecal Drug Delivery (ITDD) systems for cancer pain. F1000Res. 2013;2:96. doi:10.12688/f1000research.2-96.v1
  • Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20(2):133–154. doi:10.1111/ner.12543
  • Brogan SE. Intrathecal therapy for the management of cancer pain. Curr Pain Headache Rep. 2006;10(4):254–259. doi:10.1007/s11916-006-0029-8
  • Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17(12):2404–2421. doi:10.1093/pm/pnw060
  • Upadhyay SP, Mallick PN. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates. Am J Hosp Palliat Care. 2012;29(5):388–398. doi:10.1177/1049909111426134
  • Kim EK, Shin JY, Castaneda AM, et al. Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea. Korean J Pain. 2017;30(4):272–280. doi:10.3344/kjp.2017.30.4.272
  • Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit. Pain Med. 2013;14(4):478–486. doi:10.1111/pme.12060
  • Kim EJ, Moon JY, Kim YC, Park KS, Yoo YJ. Intrathecal morphine infusion therapy in management of chronic pain: present and future implementation in Korea. Yonsei Med J. 2016;57(2):475–481. doi:10.3349/ymj.2016.57.2.475
  • Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97(4):803–810. doi:10.3171/jns.2002.97.4.0803
  • Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10(5):348–355. doi:10.1016/0885-3924(95)00052-Z
  • Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5):504–515. doi:10.1177/0269216311406577
  • Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011;14(3):219–248.
  • Kim JH, Jung JY, Cho MS. Continuous intrathecal morphine administration for cancer pain management using an intrathecal catheter connected to a subcutaneous injection port: a retrospective analysis of 22 terminal cancer patients in korean population. Korean J Pain. 2013;26(1):32–38. doi:10.3344/kjp.2013.26.1.32
  • Hattori S, Sano H, Tanaka K, Yokota M. Intrathecal morphine treatment in advanced cancer pain patients. Masui. 2009;58(11):1384–1392.
  • Zheng S, He L, Yang X, Li X, Yang Z. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore). 2017;96(11):e6354. doi:10.1097/MD.0000000000006354
  • Kleinmann B, Wolter T. Managing chronic non-malignant pain in the elderly: intrathecal therapy. Drugs Aging. 2019;36(9):789–797. doi:10.1007/s40266-019-00692-7
  • Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med. 2019;20(4):784–798. doi:10.1093/pm/pny132
  • Dupoiron D. Intrathecal therapy for pain in cancer patients. Curr Opin Support Palliat Care. 2019;13(2):75–80. doi:10.1097/SPC.0000000000000427
  • Kleinmann B, Wolter T. Intrathecal opioid therapy for non-malignant chronic pain: a long-term perspective. Neuromodulation. 2017;20(7):719–726. doi: 10.1111/ner.12617
  • Reina MA, Lopez-Garcia A, Dittmann M, de Andres JA. Structural analysis of the thickness of human dura mater with scanning electron microscopy. Rev Esp Anestesiol Reanim. 1996;43(4):135–137.
  • Wallace M, Yaksh TL. Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans. Anesth Analg. 2012;115(4):797–804. doi:10.1213/ANE.0b013e3182645dfd
  • Tangen KM, Leval R, Mehta AI, Linninger AA. Computational and in vitro experimental investigation of intrathecal drug distribution: parametric study of the effect of injection volume, cerebrospinal fluid pulsatility, and drug uptake. Anesth Analg. 2017;124(5):1686–1696. doi:10.1213/ANE.0000000000002011
  • Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–4049. doi:10.1200/JCO.2002.02.118
  • Adler JA, Lotz NM. Intrathecal pain management: a team-based approach. J Pain Res. 2017;10:2565–2575. doi:10.2147/JPR.S142147